ABT vs FRT · P/E 25, rev $44.33B vs rev $1.28B
Abbott Laboratories (ABT) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
FRT (FRT) common stock.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. FRT currently screens at market cap $0.
Not investment advice. Open the ABT and FRT stock pages for the full models.
Not investment advice.